Hospital adoption of biosimilars increased dramatically over a 5-year period for three oncology biologics. Hospitals' profit margins from these drugs also rose significantly. The data comes from receivables and information on the acquisition of medicines. Adoption of biosimilars in oncology is influenced by financial conversations in hospitals. The study analyzed purchase and profit data. The findings show a direct link between finances and the adoption of biosimilars. Hospitals have made higher margins thanks to these cheaper alternatives to original drugs.